Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Change in Receivables (2021 - 2023)

Acro Biomedical has reported Change in Receivables over the past 3 years, most recently at -$18500.0 for Q3 2023.

  • Quarterly results put Change in Receivables at -$18500.0 for Q3 2023, up 97.01% from a year ago — trailing twelve months through Jun 2024 was -$18500.0 (up 95.36% YoY), and the annual figure for FY2023 was -$158500.0, down 491.36%.
  • Change in Receivables for Q3 2023 was -$18500.0 at Acro Biomedical, up from -$110000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for ACBM hit a ceiling of $599000.0 in Q2 2022 and a floor of -$619000.0 in Q3 2022.
  • Median Change in Receivables over the past 3 years was -$70000.0 (2023), compared with a mean of -$89500.0.
  • Biggest five-year swings in Change in Receivables: surged 160.2% in 2022 and later crashed 118.36% in 2023.
  • Acro Biomedical's Change in Receivables stood at -$598000.0 in 2021, then surged by 160.2% to $360000.0 in 2022, then crashed by 105.14% to -$18500.0 in 2023.
  • The last three reported values for Change in Receivables were -$18500.0 (Q3 2023), -$110000.0 (Q2 2023), and -$30000.0 (Q1 2023) per Business Quant data.